Which of the following inhalational agent is contraindicated in renal disease –
**Question:** Which of the following inhalational agent is contraindicated in renal disease -
A. Sevoflurane
B. Desflurane
C. Isoflurane
D. Entonox (mixture of nitrous oxide and oxygen)
**Core Concept:**
Inhalational anesthetic agents are volatile gases that are used for general anesthesia and sedation. They are classified into two groups: halogenated ethers (e.g., isoflurane, sevoflurane) and nitrous oxide (e.g., desflurane, nitrous oxide). Inhalational agents are eliminated from the body primarily via the lungs, and secondarily via the kidneys. In renal disease, the clearance of these agents is reduced, leading to higher blood concentrations and potential adverse effects.
**Why the Correct Answer is Right:**
The correct answer, Entonox (mixture of nitrous oxide and oxygen), is contraindicated in renal disease due to the presence of nitrous oxide. Nitrous oxide is a potent diuretic and can cause a significant reduction in renal blood flow and glomerular filtration rate. This can lead to further deterioration of renal function in patients with preexisting renal impairment.
**Why Each Wrong Option is Incorrect:**
A. Sevoflurane and isoflurane are both halogenated ethers, which are primarily eliminated via lungs and to a lesser extent via kidneys. Although there is a theoretical concern regarding their elimination in renal disease, the clinical significance is minimal due to their low blood-gas solubility and low affinity for plasma proteins.
B. Desflurane is another halogenated ether anesthetic agent, and its elimination is similar to sevoflurane and isoflurane. In renal disease, desflurane's elimination via the lungs remains unimpaired, but its elimination via the kidneys is reduced, leading to higher blood concentrations and potential adverse effects.
C. Isoflurane is primarily eliminated via lungs and is not significantly affected by renal disease. However, the clinical significance of renal disease on isoflurane elimination should be kept in mind, as it is the most commonly used agent in clinical practice.
**Clinical Pearl:**
Renal function should be assessed in patients with any significant risk factors, such as advanced age, diabetes, hypertension, or pre-existing renal disease. Anesthesia providers should have a low threshold for monitoring renal function tests in these patients to ensure safe administration of inhalational anesthetic agents. In patients with severely compromised renal function, alternative anesthetic techniques or regional anesthesia should be considered to minimize the risk of anesthetic-related complications.